药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Polatuzumab vedotin.
Difenoxin
Coltuximab ravtansine
The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Polatuzumab vedotin.
Difenoxin
AVE9633
The risk or severity of adverse effects can be increased when AVE9633 is combined with Polatuzumab vedotin.
Difenoxin
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Polatuzumab vedotin.
Difenoxin
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Polatuzumab vedotin.
Difenoxin
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Polatuzumab vedotin.
Difenoxin
Naratuximab emtansine
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Naratuximab emtansine.
Difenoxin
Lorukafusp alfa
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lorukafusp alfa.
Difenoxin
Lulizumab pegol
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lulizumab pegol.
Difenoxin
Pinatuzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Pinatuzumab vedotin.
Difenoxin
Vesencumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Vesencumab.
Difenoxin
Tomaralimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tomaralimab.
Difenoxin
Ladiratuzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ladiratuzumab vedotin.
Difenoxin
GMA-161
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with GMA-161.
Difenoxin
Pidilizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Pidilizumab.
Difenoxin
Istiratumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Istiratumab.
Difenoxin
Evinacumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Evinacumab.
Difenoxin
Sofituzumab vedotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sofituzumab vedotin.
Difenoxin
Valanafusp alfa
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Valanafusp alfa.
Difenoxin
Gedivumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Gedivumab.